Free Trial
Your $100 Credit Is Waiting! Get MarketBeat All Access Today
Lock In $149
Claim MarketBeat All Access Sale Promotion

Immunovant (IMVT) Financials

Immunovant logo
$35.56 +9.27 (+35.26%)
Closing price 04:00 PM Eastern
Extended Trading
$35.52 -0.04 (-0.10%)
As of 06:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Immunovant

Annual Income Statements for Immunovant

This table shows Immunovant's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 3/31/2019 3/31/2020 3/31/2021 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -29 -66 -107 -107 -157 -211 -259 -414
Consolidated Net Income / (Loss)		 -29 -66 -107 -107 -157 -211 -259 -414
Net Income / (Loss) Continuing Operations		 -29 -66 -107 -107 -157 -211 -259 -414
Total Pre-Tax Income 		-29 -66 -108 -108 -157 -211 -259 -413
Total Operating Income		 -28 -66 -108 -108 -156 -218 -283 -438
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 28 66 108 108 156 218 283 438
Selling, General & Admin Expense		 2.69 18 40 40 54 48 57 77
Research & Development Expense		 26 48 69 69 102 170 225 361
Total Other Income / (Expense), net		 -0.16 -0.21 0.33 0.33 -0.78 7.33 24 25
Interest & Investment Income		 - - - - - 7.58 25 25
Other Income / (Expense), net		 -0.16 0.41 0.33 0.33 -0.78 -0.25 -1.01 0.47
Income Tax Expense		 0.02 0.10 -0.36 -0.36 -0.08 0.01 0.57 0.89
Basic Earnings per Share		 ($1.29) ($1.54) ($1.22) ($1.22) ($1.43) ($1.71) ($1.88) ($2.73)
Weighted Average Basic Shares Outstanding		 22.17M 43.20M 87.76M 97.98M 109.68M 123.08M 138.10M 151.57M
Diluted Earnings per Share		 ($1.29) ($1.54) ($1.22) ($1.22) ($1.43) ($1.71) ($1.88) ($2.73)
Weighted Average Diluted Shares Outstanding		 22.17M 43.20M 87.76M 97.98M 109.68M 123.08M 138.10M 151.57M
Weighted Average Basic & Diluted Shares Outstanding		 22.17M 43.20M 87.76M 87.76M 116.51M 130.41M 146.05M 170.92M

Quarterly Income Statements for Immunovant

This table shows Immunovant's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -74 -59 -51 -75 -87 -109 -111 -106 -121 -127 -111
Consolidated Net Income / (Loss)		 -74 -59 -51 -75 -87 -109 -111 -106 -121 -127 -111
Net Income / (Loss) Continuing Operations		 -74 -59 -51 -75 -87 -109 -111 -106 -121 -127 -111
Total Pre-Tax Income 		-74 -58 -52 -75 -87 -109 -111 -106 -120 -126 -109
Total Operating Income		 -78 -62 -62 -81 -94 -116 -114 -114 -127 -132 -114
Total Gross Profit		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses		 78 62 62 81 94 116 114 114 127 132 114
Selling, General & Admin Expense		 15 14 13 15 19 18 20 20 26 18 15
Research & Development Expense		 63 48 48 66 75 97 95 94 101 114 99
Total Other Income / (Expense), net		 4.53 3.59 10 5.79 7.21 6.70 3.33 7.96 7.52 5.85 5.28
Interest & Investment Income		 4.07 3.57 8.93 - 7.18 6.07 4.59 6.89 6.34 5.60 5.33
Other Income / (Expense), net		 0.46 0.02 1.09 -2.59 0.03 0.63 -1.26 1.07 1.19 0.25 -0.05
Income Tax Expense		 -0.01 0.45 -0.11 0.23 0.08 0.08 0.15 0.58 0.91 0.59 1.55
Basic Earnings per Share		 ($0.57) ($0.45) ($0.36) ($0.50) ($0.60) ($0.74) ($0.76) ($0.63) ($0.71) ($0.73) ($0.61)
Weighted Average Basic Shares Outstanding		 130.50M 131.16M 144.52M 138.10M 146.09M 146.47M 146.92M 151.57M 170.87M 173.64M 181.51M
Diluted Earnings per Share		 ($0.57) ($0.45) ($0.36) ($0.50) ($0.60) ($0.74) ($0.76) ($0.63) ($0.71) ($0.73) ($0.61)
Weighted Average Diluted Shares Outstanding		 130.50M 131.16M 144.52M 138.10M 146.09M 146.47M 146.92M 151.57M 170.87M 173.64M 181.51M
Weighted Average Basic & Diluted Shares Outstanding		 130.67M 144.66M 145.29M 146.05M 146.37M 146.78M 169.86M 170.92M 174.32M 175.28M 203.53M

Annual Cash Flow Statements for Immunovant

This table details how cash moves in and out of Immunovant's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 3/31/2019 3/31/2020 3/31/2021 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025
Net Change in Cash & Equivalents		 6.99 94 300 300 94 -117 259 79
Net Cash From Operating Activities		 -29 -53 -83 -83 -106 -188 -214 -376
Net Cash From Continuing Operating Activities		 -29 -53 -83 -83 -106 -188 -214 -376
Net Income / (Loss) Continuing Operations		 -29 -66 -107 -107 -157 -211 -259 -414
Consolidated Net Income / (Loss)		 -29 -66 -107 -107 -157 -211 -259 -414
Depreciation Expense		 0.01 0.02 0.07 0.07 0.13 0.19 0.23 0.38
Amortization Expense		 - 0.00 - 0.93 - 1.13 1.13 0.13
Non-Cash Adjustments To Reconcile Net Income		 1.49 8.20 19 19 35 32 41 50
Changes in Operating Assets and Liabilities, net		 -1.45 4.81 4.57 4.57 15 -11 2.63 -12
Net Cash From Investing Activities		 -0.05 -0.03 -0.21 -0.21 -0.25 -0.20 -0.36 -0.76
Net Cash From Continuing Investing Activities		 -0.05 -0.03 -0.21 -0.21 -0.25 -0.20 -0.36 -0.76
Purchase of Property, Plant & Equipment		 -0.05 -0.03 -0.21 -0.21 -0.25 -0.20 -0.36 -0.76
Net Cash From Financing Activities		 36 147 383 383 200 71 472 454
Net Cash From Continuing Financing Activities		 36 147 383 383 200 71 472 454
Repurchase of Common Equity		 -0.52 -3.11 -1.24 -1.24 0.00 -0.27 -6.01 -0.32
Issuance of Common Equity		 20 0.00 386 386 200 71 473 450
Other Financing Activities, net		 16 112 1.10 1.10 0.13 0.66 5.69 4.81
Effect of Exchange Rate Changes		 - - - - -0.09 0.22 0.99 0.75
Cash Income Taxes Paid		 0.07 0.06 0.17 0.17 - 0.00 0.51 1.20

Quarterly Cash Flow Statements for Immunovant

This table details how cash moves in and out of Immunovant's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Change in Cash & Equivalents		 -47 -60 421 -56 -75 -87 -98 339 -115 -77 473
Net Cash From Operating Activities		 -47 -60 -47 -60 -76 -89 -100 -111 -117 -103 -92
Net Cash From Continuing Operating Activities		 -47 -60 -47 -60 -76 -89 -100 -111 -117 -103 -92
Net Income / (Loss) Continuing Operations		 -74 -59 -51 -75 -87 -109 -111 -106 -121 -127 -111
Consolidated Net Income / (Loss)		 -74 -59 -51 -75 -87 -109 -111 -106 -121 -127 -111
Depreciation Expense		 0.05 0.06 0.06 0.06 0.08 0.09 0.10 0.11 0.11 0.11 0.10
Amortization Expense		 0.29 0.29 0.30 - - 0.02 0.02 0.02 - - 0.03
Non-Cash Adjustments To Reconcile Net Income		 11 11 10 8.89 14 13 12 12 19 13 13
Changes in Operating Assets and Liabilities, net		 16 -12 -6.25 5.63 -2.65 7.67 -1.04 -16 -15 11 5.47
Net Cash From Financing Activities		 0.89 0.15 470 1.55 0.69 0.73 2.46 451 2.92 25 565
Net Cash From Continuing Financing Activities		 0.89 0.15 470 1.55 0.69 0.73 2.46 451 2.92 25 565
Other Financing Activities, net		 0.89 0.15 3.11 1.55 0.69 0.73 2.46 0.93 2.92 25 21
Effect of Exchange Rate Changes		 -0.05 -0.09 -1.61 2.73 0.34 1.05 -0.15 -0.49 -0.57 0.88 0.38
Cash Income Taxes Paid		 - - - - - - - 0.90 - - 1.64

Annual Balance Sheets for Immunovant

This table presents Immunovant's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 3/31/2020 3/31/2021 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025
Total Assets		 0.41 109 412 412 516 406 666 776
Total Current Assets		 0.33 109 409 409 513 404 666 768
Cash & Equivalents		 0.33 101 400 400 494 377 635 714
Accounts Receivable		 - - 0.60 - 12 0.70 5.34 2.08
Prepaid Expenses		 0.00 5.46 7.72 8.86 6.25 27 25 52
Plant, Property, & Equipment, net		 0.00 0.07 0.20 0.20 0.33 0.33 0.46 0.84
Total Noncurrent Assets		 0.08 0.25 3.28 3.28 2.30 1.17 0.13 7.62
Other Noncurrent Operating Assets		 0.08 0.25 3.28 3.28 2.30 1.17 0.13 7.62
Total Liabilities & Shareholders' Equity		 0.41 109 412 412 516 406 666 776
Total Liabilities		 0.38 15 21 21 46 43 49 69
Total Current Liabilities		 0.38 15 19 19 45 43 49 69
Accounts Payable		 - 4.38 2.43 2.43 19 1.35 7.16 18
Accrued Expenses		 0.08 11 15 15 25 40 41 51
Total Noncurrent Liabilities		 0.00 0.00 2.24 2.24 1.22 0.05 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 0.02 94 391 391 470 362 618 707
Total Preferred & Common Equity		 0.02 94 391 391 470 362 618 707
Preferred Stock		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 0.02 94 391 391 470 362 618 707
Common Stock		 0.03 185 590 590 825 928 1,442 1,946
Retained Earnings		 -0.00 -91 -199 -199 -355 -566 -826 -1,240
Accumulated Other Comprehensive Income / (Loss)		 - -0.02 -0.30 -0.30 0.40 0.85 1.91 1.46

Quarterly Balance Sheets for Immunovant

This table presents Immunovant's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2022 12/31/2022 6/30/2023 9/30/2023 12/31/2023 6/30/2024 9/30/2024 12/31/2024 6/30/2025 9/30/2025 12/31/2025
Total Assets		 428 456 351 292 711 590 516 421 661 583 1,052
Total Current Assets		 426 454 350 291 711 589 507 413 652 574 1,043
Cash & Equivalents		 406 433 330 270 691 560 473 375 599 522 995
Accounts Receivable		 3.78 0.70 0.82 1.42 1.03 2.42 1.88 2.22 1.94 1.97 1.64
Prepaid Expenses		 17 21 19 20 19 27 33 36 51 50 47
Plant, Property, & Equipment, net		 0.31 0.36 0.33 0.30 0.38 0.57 0.67 0.75 0.74 0.63 0.53
Total Noncurrent Assets		 1.74 1.46 0.88 0.59 0.29 0.07 7.66 7.64 8.94 8.78 8.92
Other Noncurrent Operating Assets		 1.74 1.46 0.88 0.59 0.29 0.07 7.66 7.64 8.94 8.78 8.92
Total Liabilities & Shareholders' Equity		 428 456 351 292 711 590 516 421 661 583 1,052
Total Liabilities		 32 42 51 40 32 45 67 68 53 63 66
Total Current Liabilities		 32 41 51 40 32 45 67 68 53 63 66
Accounts Payable		 7.46 14 26 7.51 3.91 11 21 20 7.84 6.92 8.62
Accrued Expenses		 23 26 24 32 28 34 46 48 45 56 58
Total Noncurrent Liabilities		 0.61 0.31 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 396 415 300 252 679 545 449 353 609 520 986
Total Preferred & Common Equity		 396 415 300 252 679 545 449 353 609 520 986
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 396 415 300 252 679 545 449 353 609 520 986
Common Stock		 841 920 940 950 1,430 1,456 1,469 1,483 1,967 2,005 2,582
Retained Earnings		 -444 -507 -640 -699 -750 -913 -1,022 -1,133 -1,360 -1,487 -1,597
Accumulated Other Comprehensive Income / (Loss)		 -1.24 1.38 0.58 0.51 -0.60 1.82 1.91 2.48 1.74 1.45 1.20

Annual Metrics And Ratios for Immunovant

This table displays calculated financial ratios and metrics derived from Immunovant's official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 3/31/2019 3/31/2020 3/31/2021 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025
Growth Metrics		 - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -129.77% -64.10% 0.87% 0.00% -38.62% -30.00% -54.83%
EBIT Growth		 0.00% -129.76% -64.15% 0.00% 0.00% -39.36% -29.83% -54.27%
NOPAT Growth		 0.00% -132.46% -63.62% 0.00% 0.00% -39.89% -29.52% -54.98%
Net Income Growth		 0.00% -132.13% -61.82% 0.00% 0.00% -34.60% -22.93% -59.58%
EPS Growth		 0.00% -19.38% 20.78% 0.00% 0.00% -19.58% -9.94% -45.21%
Operating Cash Flow Growth		 0.00% -86.91% -56.17% 0.00% 0.00% -77.35% -13.83% -75.46%
Free Cash Flow Firm Growth		 0.00% 0.00% -84.94% -2.94% 0.00% 0.00% -19.40% -63.53%
Invested Capital Growth		 0.00% -1,451,239.29% -33.28% 0.00% 0.00% 41.49% -25.43% 62.95%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -23.71% 31.72% 0.00% 0.00% -6.98% -7.23%
EBIT Q/Q Growth		 0.00% 0.00% -23.76% 31.12% 0.00% 0.00% -7.41% -7.17%
NOPAT Q/Q Growth		 0.00% 0.00% -24.13% 30.32% 0.00% 0.00% -6.25% -8.13%
Net Income Q/Q Growth		 0.00% 0.00% -22.75% 30.64% 0.00% 0.00% -6.53% -8.13%
EPS Q/Q Growth		 0.00% 0.00% 31.46% -5.17% 0.00% 0.00% -2.17% -5.00%
Operating Cash Flow Q/Q Growth		 0.00% -24.21% -56.17% 26.81% 0.00% -13.81% -1.86% -15.68%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 24.92% 0.00% 0.00% 0.00% -16.33%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% -10.79% 0.00% 0.00% -51.88% 70.44%
Profitability Metrics		 - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.07% 100.15% 99.67% 99.67% 99.95% 100.00% 100.22% 100.22%
Interest Burden Percent		 100.00% 100.95% 100.00% 100.00% 100.00% 96.53% 91.21% 94.35%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -116,483.38% -141.11% -44.25% -27.44% -33.36% -50.69% -52.91% -62.46%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -116,483.38% -141.11% -44.25% -27.44% -33.36% -50.69% -52.91% -62.46%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -70.57% -27.44% 0.00% -33.36% -58.20% -41.98% -58.50%
Net Operating Profit after Tax (NOPAT)		 -20 -46 -76 -76 -109 -153 -198 -307
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -34,806.00% -40.03% -12.68% -7.93% -9.62% -13.37% -12.14% -15.88%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -19.33% - - - -43.35%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -29 -66 -108 -108 -157 -219 -284 -438
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -29 -66 -108 -107 -157 -217 -282 -437
Valuation Ratios		 - - - - - - - -
Price to Book Value (P/BV)		 4,072.99 9.34 4.01 4.01 1.37 5.57 7.60 4.10
Price to Tangible Book Value (P/TBV)		 4,072.99 9.34 4.01 4.01 1.37 5.57 7.60 4.10
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - -
Debt to Equity		 12.22 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.07 -1.03 -1.02 -1.05 -1.05 -1.03 -1.02
Leverage Ratio		 16.50 1.17 1.07 1.05 1.10 1.11 1.09 1.09
Compound Leverage Factor		 16.50 1.18 1.07 1.05 1.10 1.07 1.00 1.03
Debt to Total Capital		 92.44% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 92.44% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 7.56% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -75.33 32.30 44.48 44.48 7.53 25.30 55.92 22.31
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - -
Current Ratio		 0.85 7.12 21.79 21.79 11.52 9.34 13.70 11.16
Quick Ratio		 0.85 6.57 21.35 21.32 11.37 8.71 13.18 10.41
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -40 -74 -76 0.00 -163 -194 -318
Operating Cash Flow to CapEx		 -54,898.08% -172,119.35% -39,679.52% -39,679.52% -41,776.38% -95,529.44% -59,507.50% -49,522.27%
Free Cash Flow to Firm to Interest Expense		 0.00 -63.60 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 -85.37 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -85.42 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 -0.00 -6.50 -8.67 -8.67 -24 -14 -18 -6.52
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -6.50 -2.16 0.00 0.00 9.95 -3.57 11
Enterprise Value (EV)		 100 778 1,171 1,171 148 1,644 4,059 2,189
Market Capitalization		 100 879 1,571 1,571 641 2,020 4,694 2,903
Book Value per Share		 $0.00 $1.67 $4.00 $4.00 $4.04 $2.78 $4.25 $4.16
Tangible Book Value per Share		 $0.00 $1.67 $4.00 $4.00 $4.04 $2.78 $4.25 $4.16
Total Capital		 0.32 94 391 391 470 362 618 707
Total Debt		 0.30 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -0.03 -101 -400 -400 -494 -377 -635 -714
Capital Expenditures (CapEx)		 0.05 0.03 0.21 0.21 0.25 0.20 0.36 0.76
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.08 -6.81 -9.91 -9.91 -25 -15 -18 -15
Debt-free Net Working Capital (DFNWC)		 0.24 94 390 390 468 361 617 699
Net Working Capital (NWC)		 -0.06 94 390 390 468 361 617 699
Net Nonoperating Expense (NNE)		 8.70 20 32 32 48 58 61 107
Net Nonoperating Obligations (NNO)		 -0.03 -101 -400 -400 -494 -377 -635 -714
Total Depreciation and Amortization (D&A)		 0.01 0.02 0.07 1.00 0.13 1.32 1.36 0.51
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($1.22) ($1.22) ($1.43) ($1.71) ($1.88) ($2.73)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 97.98M 97.98M 109.68M 123.08M 138.10M 151.57M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($1.22) ($1.22) ($1.43) ($1.71) ($1.88) ($2.73)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 97.98M 97.98M 109.68M 123.08M 138.10M 151.57M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($1.22) ($1.22) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 87.76M 87.76M 116.51M 130.41M 146.05M 170.92M
Normalized Net Operating Profit after Tax (NOPAT)		 -20 -46 -76 -76 -109 -153 -198 -307
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - -
EBIT to Interest Expense		 0.00 -105.07 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 -74.01 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 -105.12 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 -74.06 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -1.82% -4.68% -1.15% -1.15% 0.00% -0.13% -2.32% -0.08%

Quarterly Metrics And Ratios for Immunovant

This table displays calculated financial ratios and metrics derived from Immunovant's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -94.29% -25.95% 8.56% -30.62% -21.16% -87.21% -92.06% -35.45% -33.72% -14.24% 0.99%
EBIT Growth		 -94.93% -26.54% 8.09% -30.61% -20.82% -86.33% -91.14% -35.09% -33.72% -14.25% 0.99%
NOPAT Growth		 -94.37% -24.56% 3.86% -25.86% -20.14% -87.29% -85.70% -40.74% -34.94% -13.84% -0.05%
Net Income Growth		 -83.13% -22.40% 18.68% -26.73% -17.87% -86.01% -116.12% -41.33% -38.40% -15.93% 0.44%
EPS Growth		 -62.86% -9.76% 26.53% -8.70% -5.26% -64.44% -111.11% -26.00% -18.33% 1.35% 19.74%
Operating Cash Flow Growth		 28.03% -197.53% -1.52% -7.00% -60.86% -47.60% -113.15% -85.32% -54.08% -15.64% 8.03%
Free Cash Flow Firm Growth		 0.00% -42.35% -1.40% 0.00% -419.24% -113.97% -40.69% -71.10% -41.22% -51.44% -34.79%
Invested Capital Growth		 -424.02% -80.72% 35.34% -25.43% 49.01% -31.85% -90.36% 62.95% 162.74% 90.94% 61.98%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -21.65% 20.91% 2.16% -38.08% -12.84% -22.20% -0.38% 2.44% -11.82% -4.35% 13.03%
EBIT Q/Q Growth		 -22.08% 20.81% 2.14% -38.05% -12.93% -22.13% -0.39% 2.43% -11.78% -4.34% 13.00%
NOPAT Q/Q Growth		 -22.12% 21.25% 0.40% -31.40% -16.57% -22.76% 1.25% 0.42% -11.77% -3.57% 13.21%
Net Income Q/Q Growth		 -24.41% 20.66% 12.35% -46.48% -15.71% -25.21% -1.84% 4.21% -13.31% -4.88% 12.54%
EPS Q/Q Growth		 -23.91% 21.05% 20.00% -38.89% -20.00% -23.33% -2.70% 17.11% -12.70% -2.82% 16.44%
Operating Cash Flow Q/Q Growth		 15.10% -26.79% 21.58% -26.75% -27.64% -16.34% -13.25% -10.21% -6.12% 12.69% 9.94%
Free Cash Flow Firm Q/Q Growth		 0.00% -126.15% -40.54% -7.33% -52.22% 6.81% 7.59% -30.52% -25.64% 0.07% 17.75%
Invested Capital Q/Q Growth		 -114.38% 39.80% 36.01% -51.88% 12.85% -55.67% 7.62% 70.44% 247.58% -122.49% -287.53%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 99.99% 100.78% 99.79% 100.31% 100.09% 100.07% 100.14% 100.55% 100.76% 100.47% 101.42%
Interest Burden Percent		 94.79% 94.22% 85.22% 89.96% 92.38% 94.72% 96.03% 93.89% 94.97% 95.74% 95.34%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -66.41% -78.84% -44.51% -52.91% -64.54% -92.17% -74.17% -62.46% -77.58% -95.93% -69.35%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3,684.46% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -66.41% -78.84% -44.51% -52.91% -64.54% -92.17% -74.17% -62.46% -77.58% -95.93% -69.35%
Return on Equity Simple (ROE_SIMPLE)		 -81.54% -101.37% -35.84% 0.00% -50.04% -71.93% -108.53% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -55 -43 -43 -57 -66 -81 -80 -80 -89 -92 -80
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -5.02% -4.56% -1.48% -3.70% -4.75% -7.57% -5.84% -3.97% -5.45% -6.89% -4.47%
Return On Investment Capital (ROIC_SIMPLE)		 - - -6.34% - - - -22.69% -11.26% -14.63% -17.75% -8.12%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -78 -62 -60 -83 -94 -115 -116 -113 -126 -132 -114
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -78 -61 -60 -83 -94 -115 -115 -113 -126 -131 -114
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 8.25 19.92 8.97 7.60 7.08 9.29 10.31 4.10 4.49 5.41 4.52
Price to Tangible Book Value (P/TBV)		 8.25 19.92 8.97 7.60 7.08 9.29 10.31 4.10 4.49 5.41 4.52
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 221.84 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.03 -1.04 -1.03 -1.03 -1.05 -1.06 -1.03 -1.02 -1.01 -1.03 -1.02
Leverage Ratio		 1.10 1.11 1.07 1.09 1.11 1.15 1.10 1.09 1.08 1.13 1.10
Compound Leverage Factor		 1.04 1.05 0.91 0.98 1.03 1.09 1.05 1.02 1.03 1.09 1.05
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 26.64 71.75 113.30 56.91 49.80 35.08 28.24 23.69 28.60 23.39 38.98
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.82 7.23 22.14 13.70 13.08 7.61 6.04 11.16 12.32 9.07 15.74
Quick Ratio		 6.44 6.74 21.56 13.18 12.49 7.12 5.52 10.41 11.36 8.28 15.03
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -16 -35 -49 -53 -81 -75 -70 -91 -114 -114 -94
Operating Cash Flow to CapEx		 -105,266.67% -176,647.06% -35,952.67% -39,799.33% -41,867.58% -45,228.06% -55,772.78% -55,043.28% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -30 -18 -12 -18 -15 -24 -22 -6.52 9.63 -2.17 -8.39
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -39 -8.09 6.34 -3.57 15 -5.77 -10 11 25 22 14
Enterprise Value (EV)		 2,144 4,747 5,404 4,059 3,296 3,700 3,261 2,189 2,136 2,288 3,461
Market Capitalization		 2,474 5,016 6,095 4,694 3,856 4,173 3,636 2,903 2,735 2,810 4,456
Book Value per Share		 $2.30 $1.93 $4.70 $4.25 $3.73 $3.07 $2.40 $4.16 $3.56 $2.98 $5.63
Tangible Book Value per Share		 $2.30 $1.93 $4.70 $4.25 $3.73 $3.07 $2.40 $4.16 $3.56 $2.98 $5.63
Total Capital		 300 252 679 618 545 449 353 707 609 520 986
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -330 -270 -691 -635 -560 -473 -375 -714 -599 -522 -995
Capital Expenditures (CapEx)		 0.05 0.03 0.13 0.15 0.18 0.20 0.18 0.20 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -31 -19 -12 -18 -16 -32 -30 -15 -0.05 -12 -18
Debt-free Net Working Capital (DFNWC)		 299 251 679 617 544 441 344 699 599 510 977
Net Working Capital (NWC)		 299 251 679 617 544 441 344 699 599 510 977
Net Nonoperating Expense (NNE)		 19 15 8.33 19 21 28 31 27 32 34 31
Net Nonoperating Obligations (NNO)		 -330 -270 -691 -635 -560 -473 -375 -714 -599 -522 -995
Total Depreciation and Amortization (D&A)		 0.34 0.35 0.35 0.06 0.15 0.11 0.12 0.13 0.11 0.11 0.13
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.57) ($0.45) ($0.36) ($0.50) ($0.60) ($0.74) ($0.76) ($0.63) ($0.71) ($0.73) ($0.61)
Adjusted Weighted Average Basic Shares Outstanding		 130.50M 131.16M 144.52M 138.10M 146.09M 146.47M 146.92M 151.57M 170.87M 173.64M 181.51M
Adjusted Diluted Earnings per Share		 ($0.57) ($0.45) ($0.36) ($0.50) ($0.60) ($0.74) ($0.76) ($0.63) ($0.71) ($0.73) ($0.61)
Adjusted Weighted Average Diluted Shares Outstanding		 130.50M 131.16M 144.52M 138.10M 146.09M 146.47M 146.92M 151.57M 170.87M 173.64M 181.51M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 130.67M 144.66M 145.29M 146.05M 146.37M 146.78M 169.86M 170.92M 174.32M 175.28M 203.53M
Normalized Net Operating Profit after Tax (NOPAT)		 -55 -43 -43 -57 -66 -81 -80 -80 -89 -92 -80
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -2.47% -2.32% 0.00% 0.00% 0.00% -0.08% 0.00% 0.00% -0.20%

Financials Breakdown Chart

Key Financial Trends

Immunovant (IMVT) has shown a pattern of high cash burn with no reported revenue in the recent quarters, but carries a sizable cash runway driven by large financing inflows. Below are the key trends from the last four years, based on quarterly statements provided.

  • As of Q3 2026, Immunovant held about $994.5 million in cash and cash equivalents, creating a strong liquidity buffer for ongoing development plans.
  • Net cash from financing activities in Q3 2026 was about $564.6 million, giving the company substantial runway to fund operations and R&D without immediate debt obligations.
  • The balance sheet shows low leverage, with Total Liabilities around $66.3 million against Total Assets of about $1.05 billion, offering substantial financial flexibility.
  • Total equity stood near $986.1 million in Q3 2026, indicating a solid equity base and ongoing investor support to finance future activities.
  • Total Revenue has been zero in the reported quarters, reflecting Immunovant's early-stage clinical focus with no product sales to date.
  • Weighted average shares outstanding have been in the 170–204 million range in 2026 quarters, signaling ongoing equity dilution alongside financing activity.
  • Net income from continuing operations was negative in Q3 2026, at about -$110.6 million, highlighting a sustained bottom-line loss with no revenue yet.
  • Net cash from operating activities in Q3 2026 was about -$92.3 million, illustrating ongoing cash burn from core operations despite financing inflows.
  • R&D expenses remained high (e.g., about $98.9 million in Q3 2026) alongside substantial SG&A costs, contributing to the ongoing burn with no corresponding revenue.
  • No long-term debt is evident, but the company relies heavily on equity financing to fund its programs, which could dilute existing holders if capital needs persist.
05/20/26 04:02 PM ETAI Generated. May Contain Errors.

Immunovant Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Immunovant's fiscal year ends in March. Their fiscal year 2025 ended on March 31, 2025.

Immunovant's net income appears to be on an upward trend, with a most recent value of -$413.84 million in 2025, rising from -$28.60 million in 2018. The previous period was -$259.34 million in 2024. Find out what analysts predict for Immunovant in the coming months.

Immunovant's total operating income in 2025 was -$438.15 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $438.15 million

Over the last 7 years, Immunovant's total revenue changed from $0.00 in 2018 to $0.00 in 2025, a change of 0.0%.

Immunovant's total liabilities were at $68.78 million at the end of 2025, a 41.5% increase from 2024, and a 17,977.4% increase since 2018.

In the past 7 years, Immunovant's cash and equivalents has ranged from $325 thousand in 2018 to $713.97 million in 2025, and is currently $713.97 million as of their latest financial filing in 2025.

Over the last 7 years, Immunovant's book value per share changed from 0.00 in 2018 to 4.16 in 2025, a change of 378,527.3%.


Related Companies

Financial statements for NASDAQ:IMVT last updated on 2/7/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Trump Is Eyeing the Biggest Monetary Shift Since Nixon
On August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...
Americas Gold Company | Sponsoredtc pixel
One page of the SpaceX S-1 will move this stock overnight
When SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...
Behind the Markets | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
The $700 billion buy signal most investors are completely ignoring
Amazon, Google, Meta, and Microsoft have committed $700 billion to AI infrastructure this year - more capital ...
True Market Insiders | Sponsoredtc pixel